Literature DB >> 2369139

[Biliary and pancreatic excretion of methotrexate (MTX) and 5-FU on the MTX/5-FU sequential therapy].

Y Suda1, S Akazawa.   

Abstract

On the postoperative adjuvant MTX/5-FU sequential therapy, biliary and pancreatic excretion of both drugs was studied through the hepatic and pancreatic drainages in pancreatoduodenectomized patients. MTX: 100 mg/m2 of bolus injection and 5-FU: 800 mg/m2 of sequential one hour drip infusion were used in this series. Biliary excretion of MTX was reached peak concentration at 90 min, its mean value being 5 fold of serum concentration. During the observation period of 4.5 hours, the recovery of MTX in bile was calculated as 3-12% which presumed to be more because of still continuing biliary excretion on the terminal observation. Pancreatic excretion of MTX was minimal and not so as to have further clinical meaning. Though the serum concentration of 5-FU was raised up with its infusion, biliary and pancreatic outputs of 5-FU were small, each value showing one third compared with at a single shot of the same doses. From the obtained mode and time lag of concentration curves of both drugs, the rationale of per oral and earlier administration of Leucovorin was discussed as a possible way of removal of MTX from intestine.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2369139

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  3 in total

1.  Predicting when biliary excretion of parent drug is a major route of elimination in humans.

Authors:  Chelsea M Hosey; Fabio Broccatelli; Leslie Z Benet
Journal:  AAPS J       Date:  2014-07-09       Impact factor: 4.009

2.  Severe 5-Fluorouracil-Associated Gastrointestinal Toxicity Unexplained by Dihydropyrimidine Dehydrogenase Deficiency and Renal Impairment: Should We Be Investigating Other Elimination Pathways to Assess the Risk of 5-Fluorouracil Toxicity?

Authors:  Soo Hee Jeong; Ottiniel Chavani; Kathryn Burns; David Porter; Michael Findlay; Nuala Helsby
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-09-27       Impact factor: 2.441

Review 3.  Molecular mechanism of action and pharmacokinetic properties of methotrexate.

Authors:  V Maksimovic; Z Pavlovic-Popovic; S Vukmirovic; J Cvejic; A Mooranian; H Al-Salami; M Mikov; S Golocorbin-Kon
Journal:  Mol Biol Rep       Date:  2020-05-15       Impact factor: 2.316

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.